Pittsburgh — Cohera Medical, maker of surgical adhesive TissuGlu, is expanding its marketing efforts for the CE Mark-approved device in Europe and to complete clinical trials in the United States.
The company has secured $8.4 million toward Series D financing through private investors, according to a company news release. The funds will be used to expand the adoption of the product in Germany, where it began selling the product to hospitals in September 2011, and other European markets this year, as well as to support U.S. clinical trials.
Cohera is conducting studies in Germany and the United States, MedCity News reports. The German study involves the use of TissuGlu in 30 patients without using drains. A clinical trial in the United States includes 150 participants and is aimed at earning Food and Drug Administration approval.
TissuGlu is intended for use in plastic and reconstructive procedures that involve flap procedures. Cohera officials claim the adhesive negates the need for surgical drains.
Go back to the Cosmetic Surgery Times eNews newsletter.
